Welcome, Guest. Please login or register.
November 28, 2021, 11:10:39 pm

Login with username, password and session length


  • Total Posts: 327
  • Total Topics: 183
  • Online Today: 32
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 10
Total: 10


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Approves New Targeted Therapy for Advanced Breast Cancer  (Read 1721 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
FDA Approves New Targeted Therapy for Advanced Breast Cancer
« on: October 10, 2017, 09:11:53 am »
On September 28, the Food and Drug Administration (FDA) approved Verzenio (abemaciclib), a kinase inhibitor that disrupts cancer growth, for people with certain types of advanced or metastatic breast cancer that has progressed despite hormone therapy.

The approval was supported by data from a Phase III trial that showed that women who took Verzenio plus the estrogen blocker Faslodex (fulvestrant) after hormone therapy stopped working held off disease progression for nearly twice as long as those who took a placebo.

Breast cancer is classified by the kind of receptors it expresses. A majority of breast tumors carry hormone receptors for estrogen or progesterone (known as HR-positive). Estrogen and progesterone encourage the growth of HR-positive breast cancer, and treatment usually includes hormone-blocking drugs. Other tumors express a receptor called HER2 (human epidermal growth factor receptor 2). Triple-negative breast cancer doesn’t express any of these receptors.

The FDA approved Verzenio for adults with HR-positive/HER2-negative advanced or metastatic (spread elsewhere in the body) breast cancer that has progressed after taking hormone blockers. More than 70 percent of all breast cancers are HR-positive and HER2-negative, according to the American Cancer Society.



© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.